Skip to main content

Table 2 Baseline clinical characteristics

From: Androgen deprivation in prostate cancer: benefits of home-based resistance training

Variable UC (n = 12) PRT (n = 13) p value
Age (years) 71.8 ± 1.8 69.3 ± 2.3 0.14
Weight (kg) 79.9 ± 2.7 87.2 ± 4.7 0.03
BMI kg/m2 28.8 ± 1.1 29.7 ± 1.3 0.36
Number of co-morbiditiesa 0.9 ± 0.2 1.5 ± 0.2 0.81
Number of medications 1.1 ± 0.3 1.5 ± 1.1 0.91
SBP (mmHg) 137 ± 2 139 ± 4 0.18
DBP (mmHg) 74 ± 3 74 ± 1 0.11
Gleason score 7.6 ± 0.3 8.2 ± 0.2 0.42
Cancer staging
 Localised (n) 9 8 0.36
 Biochemical recurrence (n) 3 3
 Metastatic (n) 0 2
Previous radiotherapy (n) 8 5 0.39
Previous ADT (n) 0 2 0.26
Lean body mass (kg) 53.1 ± 1.2 54.5 ± 2.2 0.16
LBM (% body weight) 66.5 ± 1.8 63.2 ± 2.0 0.68
Fat mass (kg) 24.2 ± 2.1 29.9 ± 3.2 0.12
Extracellular water (L) 19.0 ± 0.6 19.8 ± 0.9 0.05
BCM (kg) 34.1 ± 1.0 34.7 ± 1.3 0.58
Testosterone (nmol/L) 16.1 ± 1.1 12.5 ± 0.8 0.02
LH (mIU/mL) 7.0 ± 0.7 6.3 ± 0.7 0.70
PSA (ng/mL) 10.3 ± 3.3 7.7 ± 1.3 0.08
Step count (number) 40172 ± 8502 28838 ± 5377 0.14
Light physical activity (h) 5.9 ± 1.6 7.9 ± 2.5 0.09
Moderate physical activity (h) 3.9 ± 1.8 3.3 ± 1.4 0.93
High physical activity (h) 0.1 ± 0.1 0.5 ± 0.3 0.05
  1. Data are presented as mean ± S.E.M
  2. p value is for UC vs PRT group; BMI body mass index, LBM lean body mass, BCM body cell mass, LH luteinizing hormone, PSA prostate-specific antigen
  3. aCardiovascular disease, respiratory disease, arthritis, hypertension, dyslipidemia, diabetes, osteoporosis
\